Effectiveness of Siddha medicine, Kabasura kudineer and vitamin c-zinc supplementation in the management of Mild COVID 19 patients.
Phase 1
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/05/025215
- Lead Sponsor
- Dean
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
1.Laboratory confirmed COVID-19 without symptoms
2.Consenting to participate in the study and sign the informed consent
Exclusion Criteria
1.Patient with co morbid conditions like DM, HT, BA
2.Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with COVID-19
3.Pregnant and mothers, those who have a pregnancy plan.
4.Patients with other systemic malignant diseases such as malignant tumors, mental illnesses, etc., which the researchers consider unsuitable for participation in the study
5.People who have been allergic to Siddha medicine or intolerant to taking medicine
6.Patients participating in other COVID-19 clinical trials
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in incidence of clinical symptoms of COVID 19 <br/ ><br>Negative conversion of SARS-CoV-2 <br/ ><br>Reduction in Viral load of SARS-CoV-2 at the end of treatment <br/ ><br>Examine the levels immune markers and inflammatory markersTimepoint: 14 days
- Secondary Outcome Measures
Name Time Method Reduction of in hospital time <br/ ><br>adverse events/effects <br/ ><br>Siddha Udaliyal assessment <br/ ><br>Siddha Uyir thathukkal and udal thathukkal assessmentTimepoint: 14 days